Genmab
1,954.5 DKK +2.04%10 investors are following this company
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Revenue
16.47B
EBIT %
32.3 %
P/E
29.33
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
GMAB
Daily low / high price
1,919.5 / 1,969
DKK
Market cap
129.24B DKK
Turnover
212.27M DKK
Volume
109K
Latest videos
Financial calendar
Interim report
02.05.2024
Interim report
01.08.2024
Interim report
06.11.2024
ShowingAll content types
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
Transactions in Connection with Share Buy-back Program Genmab
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools